177 related articles for article (PubMed ID: 36007551)
1. Combined anti-angiogenic and cytotoxic treatment of a solid tumour: in silico investigation of a xenograft animal model's digital twin.
Hadjicharalambous M; Ioannou E; Aristokleous N; Gazeli K; Anastassiou C; Vavourakis V
J Theor Biol; 2022 Nov; 553():111246. PubMed ID: 36007551
[TBL] [Abstract][Full Text] [Related]
2. Novel anti-angiogenic therapies for malignant gliomas.
Norden AD; Drappatz J; Wen PY
Lancet Neurol; 2008 Dec; 7(12):1152-60. PubMed ID: 19007739
[TBL] [Abstract][Full Text] [Related]
3. In-silico dynamic analysis of cytotoxic drug administration to solid tumours: Effect of binding affinity and vessel permeability.
Vavourakis V; Stylianopoulos T; Wijeratne PA
PLoS Comput Biol; 2018 Oct; 14(10):e1006460. PubMed ID: 30296260
[TBL] [Abstract][Full Text] [Related]
4. Tumour angiogenesis, anti-angiogenic therapy and chemotherapeutic resistance.
Mander KA; Finnie JW
Aust Vet J; 2018 Oct; 96(10):371-378. PubMed ID: 30255577
[TBL] [Abstract][Full Text] [Related]
5. Anti-angiogenic drug scheduling optimisation with application to colorectal cancer.
Sturrock M; Miller IS; Kang G; Hannis Arba'ie N; O'Farrell AC; Barat A; Marston G; Coletta PL; Byrne AT; Prehn JH
Sci Rep; 2018 Jul; 8(1):11182. PubMed ID: 30046049
[TBL] [Abstract][Full Text] [Related]
6. 'Accidental' anti-angiogenic drugs. anti-oncogene directed signal transduction inhibitors and conventional chemotherapeutic agents as examples.
Kerbel RS; Viloria-Petit A; Klement G; Rak J
Eur J Cancer; 2000 Jun; 36(10):1248-57. PubMed ID: 10882863
[TBL] [Abstract][Full Text] [Related]
7. Everolimus (RAD001) and anti-angiogenic cyclophosphamide show long-term control of gastric cancer growth in vivo.
Cejka D; Preusser M; Woehrer A; Sieghart W; Strommer S; Werzowa J; Fuereder T; Wacheck V
Cancer Biol Ther; 2008 Sep; 7(9):1377-85. PubMed ID: 18708754
[TBL] [Abstract][Full Text] [Related]
8. Targeting microtubules to inhibit angiogenesis and disrupt tumour vasculature: implications for cancer treatment.
Pasquier E; André N; Braguer D
Curr Cancer Drug Targets; 2007 Sep; 7(6):566-81. PubMed ID: 17896922
[TBL] [Abstract][Full Text] [Related]
9. Vascular normalisation as the stepping stone into tumour microenvironment transformation.
Magnussen AL; Mills IG
Br J Cancer; 2021 Aug; 125(3):324-336. PubMed ID: 33828258
[TBL] [Abstract][Full Text] [Related]
10. Anti-angiogenic alternatives to VEGF blockade.
Khan KA; Bicknell R
Clin Exp Metastasis; 2016 Feb; 33(2):197-210. PubMed ID: 26620208
[TBL] [Abstract][Full Text] [Related]
11. Gold Nanoparticle-Mediated Targeted Delivery of Recombinant Human Endostatin Normalizes Tumour Vasculature and Improves Cancer Therapy.
Li W; Zhao X; Du B; Li X; Liu S; Yang XY; Ding H; Yang W; Pan F; Wu X; Qin L; Pan Y
Sci Rep; 2016 Jul; 6():30619. PubMed ID: 27470938
[TBL] [Abstract][Full Text] [Related]
12. Trends and Challenges in Tumor Anti-Angiogenic Therapies.
Jászai J; Schmidt MHH
Cells; 2019 Sep; 8(9):. PubMed ID: 31540455
[TBL] [Abstract][Full Text] [Related]
13. Targeting tumor stroma and exploiting mature tumor vasculature to improve anti-cancer drug delivery.
Bouzin C; Feron O
Drug Resist Updat; 2007 Jun; 10(3):109-20. PubMed ID: 17452119
[TBL] [Abstract][Full Text] [Related]
14. Vascular phenotype identification and anti-angiogenic treatment recommendation: A pseudo-multiscale mathematical model of angiogenesis.
Hutchinson LG; Gaffney EA; Maini PK; Wagg J; Phipps A; Byrne HM
J Theor Biol; 2016 Jun; 398():162-80. PubMed ID: 26987523
[TBL] [Abstract][Full Text] [Related]
15. Computational simulations of tumor growth and treatment response: Benefits of high-frequency, low-dose drug regimens and concurrent vascular normalization.
Nikmaneshi MR; Jain RK; Munn LL
PLoS Comput Biol; 2023 Jun; 19(6):e1011131. PubMed ID: 37289729
[TBL] [Abstract][Full Text] [Related]
16. Metronomic 5-fluorouracil, oxaliplatin and irinotecan in colorectal cancer.
Fioravanti A; Canu B; Alì G; Orlandi P; Allegrini G; Di Desidero T; Emmenegger U; Fontanini G; Danesi R; Del Tacca M; Falcone A; Bocci G
Eur J Pharmacol; 2009 Oct; 619(1-3):8-14. PubMed ID: 19695243
[TBL] [Abstract][Full Text] [Related]
17. Enhanced anti-tumor and anti-angiogenic effects of metronomic cyclophosphamide combined with Endostar in a xenograft model of human lung cancer.
Wang R; Qin S; Chen Y; Li Y; Chen C; Wang Z; Zheng R; Wu Q
Oncol Rep; 2012 Aug; 28(2):439-45. PubMed ID: 22641525
[TBL] [Abstract][Full Text] [Related]
18. Metronomic chemotherapy in combination with antiangiogenic treatment induces mosaic vascular reduction and tumor growth inhibition in hepatocellular carcinoma xenografts.
Zhou F; Hu J; Shao JH; Zou SB; Shen SL; Luo ZQ
J Cancer Res Clin Oncol; 2012 Nov; 138(11):1879-90. PubMed ID: 22736027
[TBL] [Abstract][Full Text] [Related]
19. The differential effects of metronomic gemcitabine and antiangiogenic treatment in patient-derived xenografts of pancreatic cancer: treatment effects on metabolism, vascular function, cell proliferation, and tumor growth.
Yapp DT; Wong MQ; Kyle AH; Valdez SM; Tso J; Yung A; Kozlowski P; Owen DA; Buczkowski AK; Chung SW; Scudamore CH; Minchinton AI; Ng SS
Angiogenesis; 2016 Apr; 19(2):229-44. PubMed ID: 26961182
[TBL] [Abstract][Full Text] [Related]
20. A multitargeted, metronomic, and maximum-tolerated dose "chemo-switch" regimen is antiangiogenic, producing objective responses and survival benefit in a mouse model of cancer.
Pietras K; Hanahan D
J Clin Oncol; 2005 Feb; 23(5):939-52. PubMed ID: 15557593
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]